Delta Honored with the ENERGY STAR® Partner of the Year Sustained Excellence Award for the Sixth Consecutive Year

TAIPEI, March 31, 2023 — Delta, a global leading provider of power and thermal management solutions, today announced it was recognized by the U.S. Environmental Protection Agency (EPA) with the prominent 2023 ENERGY STAR® Partner of the Year for Sustained Excellence award for the sixth consecutive year. The prestigious distinction values Delta’s outstanding leadership in …

BIF releases a new study mentioning recommendations for the proposed Digital India Act

New Delhi, March 31, 2023 – Broadband India Forum (BIF), an independent policy forum and knowledge-based think-tank released a BIF-commissioned study on “Revising the Information Technology Act 2000” which has been prepared by xKDR Forum, a research and knowledge-based forum as a part of BIF’s Digital Dialogues series. The study report aims at providing recommendations …

BharatPe Group partners with Women Entrepreneurship Platform to foster women entrepreneurship in India

New Delhi, March 31, 2023: BharatPe Group, one of India’s leading names in the fintech industry, today announced its partnership with the Women Entrepreneurship Platform (WEP) with the objective of enabling women entrepreneurs across India in their journeys of self-reliance and business growth. The partnership aims to build a robust ecosystem that brings together women …

Spendings on cloud adoption witnesses surge in the new normal: Here’s what experts say

Opsio is a cloud-based managed services provider that offers a comprehensive range of services to businesses seeking to optimize their IT infrastructure. The company has established a reputation for delivering top-tier solutions that help organizations stay ahead of the curve in an ever-evolving digital landscape. Opsio focuses on bringing in great innovation and technology to …

Alembic Pharmaceuticals announces USFDA Final Approval for Brimonidine Tartrate Ophthalmic Solution, 0.15%

31 March 2023, Mumbai: Alembic Pharmaceuticals Limited (Alembic) today announced that it has received final approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Brimonidine Tartrate Ophthalmic Solution, 0.15%. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Alphagan P Ophthalmic Solution, 0.15%, of …